Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

If you suffered a loss on your Grocery Outlet Holding Corp. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of m ...

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

That is the key place. And so uh that's not you can't reroute those flows, you know. So that's the the issue faced here. And so Iran is going to continue to move its tankers through the straight of Hormuz. Essentially, it is not blocking the straight of Hormuz. It is being the gatekeeper. But there are alternatives to carg which Iran has been working on for for several years. What are those alternatives. Describe them and geo geographically locate them for us. >> Well, sure. Just outside of the straight of ...

Group 1 - Gossamer Bio, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - The company's lead pipeline candidate, Seralutinib, was evaluated in the PROSERA study, a pivotal Phase 3 trial for pulmonary arterial hypertension [2] - During the Q1 2025 earnings call, the CEO expressed optimism about the trial's results, stating that the baseline characteristics were targeted and that there was "over 90% power given the sample size," although the primary efficacy endpoint did not achieve statistical significance [3] Group 2 - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5]

Economic Vulnerability - The South Korean economy is highly vulnerable to oil imports, which has been highlighted by recent currency movements [1] - The retail sector remains resilient despite current uncertainties, with investors showing interest in overseas markets, particularly US equities, contributing to currency weakness [2] Market Sentiment and Government Policy - The South Korean government is pushing for a vibrant capital market, influenced by previous administrations and modeled after Japan's market policies [4][5] - There is a significant outflow of capital from Korean retail investors to US markets, with over $100 billion invested abroad, indicating a need to attract investment back home to stimulate a bull market [6] Market Dynamics and Risks - Concerns are growing about the sustainability of the current bull market, with potential risks resembling past boom-bust cycles [7] - Current earnings projections suggest that Korean equities are not overvalued, with the semiconductor sector experiencing significant growth, although reliance on these projections is crucial [8] Sector-Specific Insights - The tech sector is somewhat insulated from the immediate impacts of rising oil prices, but prolonged high prices could eventually affect the sector [9] - Supply chain risks, particularly concerning helium for semiconductor manufacturing, are emerging as a concern for the industry, necessitating greater independence from global supply chains [10][11] Long-Term Considerations - The macroeconomic impact of rising oil prices is immediate, but there are broader implications for various industries that need to be considered in the long term [12][13]

Core Insights - The current oil price does not accurately reflect the availability and disruption in the physical economy, as seen during the COVID crisis when prices remained stable despite empty shelves [1][2] - The rising costs of bunker fuel and jet fuel are significant indicators of the disruption to international shipping and air travel, which could have severe implications for the physical economy if not resolved soon [2][3] Geopolitical Dynamics - The geopolitical landscape is complex, with countries experiencing varying degrees of pain from the current energy crisis, leading to differing motivations for resolution [4][5] - The U.S. may suffer less compared to net energy importers, which could affect its willingness to resolve the situation quickly [6][7] Military and Strategic Considerations - The U.S. is deploying a marine expeditionary unit to Iran, potentially aiming to control critical oil export routes, which could escalate tensions further [9][11] - The control of global choke points is a key aspect of U.S. national security strategy, indicating a potential for increased military involvement in the region [11][12] Market Implications - The expectation that markets will respond rationally to geopolitical tensions may be misguided, as the underlying geostrategic factors are driving market behavior [17][18] - A significant escalation may be necessary before any resolution can be achieved, suggesting that market conditions could worsen before improving [14][18]

Core Insights - Stellantis N.V. is under investigation for potential violations of federal securities laws following a significant decline in stock value after a major announcement regarding its electric vehicle (EV) strategy [1][4]. Group 1: Timeline of Events - On January 31, 2026, Wall Street Zen downgraded Stellantis to Sell, followed by Morgan Stanley's downgrade to Equal-Weight on February 3, citing an "investment lag" [2]. - A report on February 5 indicated Stellantis was seeking European cash to mitigate tariff-related challenges, suggesting cash-flow stress [2]. - The last earnings call prior to the February 6 announcement was on October 30, 2025, and no updates were provided during the three months leading up to the write-down disclosure [2]. Group 2: February 6 Announcement - The February 6 announcement revealed that management had overestimated the pace of EV adoption, leading to a strategic reset that included suspending the 2026 dividend [3]. - Following this announcement, Stellantis shares plummeted approximately 28% in a single trading session, marking one of the worst trading days in the company's history [3]. Group 3: Investigation Focus - The investigation is centered on whether Stellantis' public communications between the Q3 2025 earnings call and the February 6 disclosure accurately reflected the company's internal understanding of its EV assets' viability and valuation [4].

Core Viewpoint - Hub Group, Inc. is under investigation for potential violations of federal securities laws following a significant accounting error that has led to a sharp decline in its stock price [1]. Group 1: Stock Performance and Market Reaction - Hub Group reached a 52-week high of $48.96 per share on February 3, 2026, but saw its shares drop to around $37 just three days later, resulting in a loss of approximately $12 per share [2]. - For an investor holding 10,000 shares, this decline translates to an estimated $120,000 decrease in portfolio value [2]. - The analyst community reacted quickly, with Stifel downgrading Hub Group from Buy to Sell and cutting its price target from $52 to $27, a 48% reduction [3]. - Baird also downgraded its rating from Outperform to Neutral, reducing its target from $47 to $29, a 38% cut [3]. Group 2: Financial Results and Accounting Issues - Hub Group reported Q4 2025 earnings per share of $0.45, slightly above the consensus estimate of $0.44, and revenue exceeded expectations [4]. - However, the positive earnings report was overshadowed by a disclosure of a restatement affecting three prior quarters and an estimated $77 million in understated costs [4]. - The market's reaction, illustrated by a 23% decline in stock price, indicates that the accounting issue is viewed as more significant than the quarterly earnings results [4].

Core Insights - Kelyniam Global reported an 85% improvement in net loss for the year ended December 31, 2025, indicating a strong recovery in the second half of the year despite a challenging start [1] - The company received FDA 510(k) clearance for its innovative Fusion™ cranial and craniofacial implants, which utilize a next-generation biomaterial [1] Financial Performance - Total revenue for 2025 was $3.053 million, an 8% decrease from $3.328 million in 2024, with a solid recovery noted in the latter half of the year [1] - Gross profit decreased to $2.387 million from $2.594 million in the previous year [1] - EBITDA was $(81,661), compared to $322,824 in 2024, while the net loss improved to $(138,555) from $(920,206) [1] - Operating loss was $(96,449), a decline from operating income of $277,037 in 2024 [1] Product Development - The Fusion™ implants are designed with Kelyniam's patented integrated fixation system and can be delivered within 24-48 hours [1] - The new biomaterial combines PEEK with biphasic calcium phosphate (BCP), enhancing mechanical strength, biocompatibility, and promoting better bone regrowth [1] Strategic Decisions - Kelyniam received unsolicited acquisition interest in late 2025 but rejected the offer, deeming it inadequate in reflecting the company's full value and long-term growth potential [1] - The company remains focused on evaluating opportunities that align with its long-term strategy and enhance shareholder value [1]